

Patient: PAIN HYB 2, 2009288

DOB: [REDACTED] Age: 30

Sex: F

Patient Identifiers: [REDACTED]

Visit Number (FIN): [REDACTED]

Client: ARUP Example Report Only
500 Chipeta Way
Salt Lake City, UT 84108

Physician: DR T. TEST

ARUP Test Code: 2009288

Collection Date: 08/23/2022

Received in lab: 08/23/2022

Completion Date: 08/24/2022

Interpretive Summary

See Note

Interpretive Consultation

DRUGS EXPECTED:

SUBOXONE (BUPRENORPHINE)

NALOXONE

XANAX (ALPRAZOLAM) [PRN]

PERCOCET (OXYCODONE)

CONSISTENT with medications provided:

SUBOXONE (BUPRENORPHINE): based on buprenorphine, norbuprenorphine

NALOXONE: naloxone may not be detected due to low bioavailability

PERCOCET (OXYCODONE): based on oxycodone, noroxycodone

XANAX (ALPRAZOLAM) : based on the absence of alprazolam and metabolite

INCONSISTENT with medications provided:

Ethyl-glucuronide: based on immunoassay detection

THC: based on immunoassay detection

Drugs Not Included in this Assay:

Acetaminophen

Interpretation depends on accuracy and completeness of patient medication information submitted by client.



Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine

Patient: PAIN HYB 2, 2009288 | Date of Birth: [REDACTED] | Sex: F | Physician: DR T. TEST
Patient Identifiers: [REDACTED] | Visit Number (FIN) [REDACTED]

Patient Results - Current *

Collection Date	8/23/2022
Creatinine, Urine	250.0
Oxycodone (cutoff 40 ng/mL)	Present
Noroxycodone (cutoff 100 ng/mL)	Present
Buprenorphine (cutoff 5 ng/mL)	Present
Norbuprenorphine (cutoff 20 ng/mL)	Present
Ethyl Glucuronide (cutoff 500 ng/mL)	Present
Marijuana Metabolite (cutoff 20 ng/mL)	Present
ARUP Accession	22-235-101093

* For details, see report on following page.

NOTE: Consecutive test results are displayed on this chart; however, this result set may be incomplete due to variations in the demographic information submitted for prior tests. If the information shown on this chart appears incomplete, please consult the patient's prior charts.

Interpretive Comments

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.

Results based on immunoassay detection that do not fit clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available at an additional fee within two weeks of specimen collection.

For medical purposes only; not valid for forensic use.

For further information, consult aruplab.com/pain.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.



Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine

Patient: PAIN HYB 2, 2009288 | Date of Birth: [REDACTED] | Sex: F | Physician: DR T. TEST
 Patient Identifiers: [REDACTED] | Visit Number (FIN): [REDACTED]

Drug Analyte	Result	Cutoff	Notes
OPIOIDS, IMMUNOASSAY			
Methadone	Not Detected	150 ng/mL	
Tramadol	Not Detected	100 ng/mL	
COCAINE, IMMUNOASSAY			
Benzoyllecgonine	Not Detected	150 ng/mL	cocaine metabolite
BARBITURATES, IMMUNOASSAY			
Barbiturates	Not Detected	200 ng/mL	detects amobarbital, butalbital, pentobarbital, phenobarbital, secobarbital, and others
OTHERS (IMMUNOASSAY OR SPECTROPHOTOMETRY)			
Ethyl glucuronide	Present	500 ng/mL	ethanol metabolite
Marijuana metabolite	Present	20 ng/mL	9-carboxy-tetrahydrocannabinol; does not distinguish between prescribed and illicit forms
PCP	Not Detected	25 ng/mL	phencyclidine
Carisoprodol	Not Detected	100 ng/mL	detects carisoprodol and meprobamate
OPIATES, MASS SPEC			
Codeine	Not Detected	40 ng/mL	
Morphine	Not Detected	20 ng/mL	also a metabolite of Codeine; may reflect poppy seed ingestion
6-acetylmorphine	Not Detected	20 ng/mL	heroin metabolite; morphine is expected
OXYCODONE-LIKE, MASS SPEC			
Oxycodone	Present	40 ng/mL	
--Noroxycodone	Present	100 ng/mL	oxycodone metabolite
Oxymorphone	Not Detected	40 ng/mL	eg, Opana; also a metabolite of oxycodone
--Noroxymorphone	Not Detected	100 ng/mL	oxymorphone metabolite; naloxone metabolite (i.e., normaloxone)
Hydrocodone	Not Detected	40 ng/mL	also a minor metabolite of Codeine; possible impurity of oxycodone
--Norhydrocodone	Not Detected	100 ng/mL	hydrocodone metabolite
Hydromorphone	Not Detected	20 ng/mL	eg, Dilaudid; also a metabolite of hydrocodone, and a minor metabolite of morphine
OPIOIDS, MASS SPEC			
Buprenorphine	Present	5 ng/mL	eg Suboxone, Subutex
--Norbuprenorphine	Present	20 ng/mL	buprenorphine metabolite
Fentanyl	Not Detected	2 ng/mL	
--Norfentanyl	Not Detected	2 ng/mL	fentanyl metabolite
Meperidine metabolite	Not Detected	50 ng/mL	normeperidine



Patient: PAIN HYB 2, 2009288
 ARUP Accession: 22-235-101093

Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine

Patient: PAIN HYB 2, 2009288 | Date of Birth: [REDACTED] | Sex: F | Physician: DR T. TEST
 Patient Identifiers: [REDACTED] | Visit Number (FIN): [REDACTED]

Drug Analyte	Result	Cutoff	Notes
Tapentadol	Not Detected	100 ng/mL	
--Tapentadol-o-sulfate	Not Detected	200 ng/mL	tapentadol metabolite
OPIOIDS ANTAGONIST, MASS SPEC			
Naloxone	Not Detected	100 ng/mL	eg, Narcan; also coformulated in Suboxone
GABA ANALOGUES, MASS SPEC			
Gabapentin	Not Detected	3,000 ng/mL	
Pregabalin	Not Detected	3,000 ng/mL	eg, Lyrica
AMPHETAMINE-LIKE, MASS SPEC			
Amphetamine	Not Detected	50 ng/mL	eg, Vyvanse; also a metabolite of methamphetamine
Methamphetamine	Not Detected	200 ng/mL	d- and l- isomers are not distinguished by this test; may reflect Vicks inhaler, Desoxyn, Selegiline, or illicit source
MDMA - Ecstasy	Not Detected	200 ng/mL	
MDA	Not Detected	200 ng/mL	also a metabolite of MDMA and MDEA
MDEA - Eve	Not Detected	200 ng/mL	
Phentermine	Not Detected	100 ng/mL	
Methylphenidate	Not Detected	100 ng/mL	eg, Ritalin, Dexmethylphenidate, Focalin, Concerta
BENZODIAZEPINE-LIKE, MASS SPEC			
Alprazolam	Not Detected	40 ng/mL	eg, Xanax
--Alpha-hydroxyalprazolam	Not Detected	20 ng/mL	alprazolam metabolite
Clonazepam	Not Detected	20 ng/mL	eg, Klonopin
--7-aminoclonazepam	Not Detected	40 ng/mL	clonazepam metabolite
Diazepam	Not Detected	50 ng/mL	eg, Valium
Nordiazepam	Not Detected	50 ng/mL	metabolite of chlordiazepoxide (Librium), clorazepate (Tranxene), diazepam, halazepam (Alapryl), prazepam (Centrax) and others
Oxazepam	Not Detected	50 ng/mL	eg, Serax; also metabolite of nordiazepam and temazepam
Temazepam	Not Detected	50 ng/mL	eg, Restoril; also a metabolite of diazepam
Lorazepam	Not Detected	60 ng/mL	eg, Ativan
Midazolam	Not Detected	20 ng/mL	eg, Versed
--Alpha-OH-Midazolam	Not Detected	20 ng/mL	midazolam metabolite
Zolpidem	Not Detected	20 ng/mL	eg, Ambien
--Zolpidem Metabolite	Not Detected	100 ng/mL	zolpidem 4-phenyl carboxylic acid
Reference interval			
Creatinine value (mg/dL)	250.0	20.0 - 400.0 mg/dL	



Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine

Patient: PAIN HYB 2, 2009288 | Date of Birth: [REDACTED] | Sex: F | Physician: DR T. TEST
Patient Identifiers: [REDACTED] | Visit Number (FIN): [REDACTED]

Additional Information

METHODOLOGIES USED

Qualitative Enzyme Immunoassay
Qualitative Liquid Chromatography-Tandem Mass Spectrometry
Quantitative Spectrophotometry

ABBREVIATIONS

MASS SPEC - Mass Spectrometry
MDA - 3,4-methylenedioxyamphetamine
MDEA - 3,4-methylenedioxy-N-ethylamphetamine
MDMA - 3,4-methylenedioxy-N-methylamphetamine

